Niche for acridine derivatives in anticancer therapy

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 9, 2013, Pages 1256-1271

  Galdino Pitta, M R ^a   Pitta, M G R ^a   Lima, M C A ^a   Galdino, S L ^a   Pitta, I R ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Acridine; Anticancer; Antitumour; Chemotherapy; Dna intercalation; Topoisomerases

Indexed keywords

1 NITRO 4 METHYL 9 AMINOETANOLYL ACRIDINE; 1 NITRO 9 HYDROXYETHYLAMINO ACRIDINE; 1,2,3,4 TETRAHYDRO 9 ACRIDINAMINE; 2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO [3, 4, 5 KL] ACRIDINE; 2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; ACRIDINE 3 CARBOXAMIDE; ACRIDINE 4 CARBOXAMIDE; ACRIDINE 4 CARBOXAMIDE AND PYRAZOLE[3,4,5 KL]ACRIDINE; ACRIDINE DERIVATIVE; ACRONINE; AMSACRINE; ASULACRINE; BRACO 19; C 1305; C 1748; CARBOPLATIN; CHLOROQUINE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DIHYDROINDOLIZINO[7,6,5 KL]ACRIDINIUM CHLORIDE; ISOQUINO[4,5 BC] ACRIDINE; MEPACRINE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; N 5,2 DI(OMEGA AMINOALKYL) 2,6 DIHYDROPYRAZOLO [3,4,5 KL]ACRIDINE 5 CARBOXAMIDE; N [4 (9 ACRIDINYLAMINO) 2 METHOXYPHENYL] CARBAMIC ACID; N [4 (9 ACRIDINYLAMINO) 3 METHOXYPHENYL] METHANESULFONAMIDE; N [4 (9 ACRIDINYLAMINO)PHENYL] CARBAMIC ACID; PYRAZOLE[3,4,5 KL]ACRIDINE 5 CARBOXAMIDE; S23906 1; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LEUKEMIA; ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL DEATH; CHAGAS DISEASE; COLON ADENOCARCINOMA; COLON CANCER; CYTOTOXICITY; DRUG MECHANISM; HORMONAL THERAPY; HUMAN; IMMUNOTHERAPY; LEUKEMIA; LUNG CANCER; LUPUS ERYTHEMATOSUS; LYMPHOMA; MALARIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RHEUMATOID ARTHRITIS; SARCOMA; SOLID TUMOR; UTERINE CERVIX CARCINOMA;

ACRIDINES; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS;

EID: 84881498574     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313090002     Document Type: Article

References (137)

1. World Health Organization. Fact sheets. http://www.who.int/ mediacentre/factsheets/fs297/en/index.html (Accessed June 11, 2011).
2. World Health Organization. http://www.who.int/topics/cancer/en/ (Accessed May 14, 2011).
3. Demeunynck, M., Charmantray, F.; Martelli A. Interest of acridine derivatives in the anticancer chemotherapy. Curr. Pharm. Des., 2001, 7(17), 1703-1724.
4. Denny, W.A. Acridine derivatives as chemotherapeutic agents. Curr. Med. Chem., 2002, 9(18), 1655-1665.
5. Moroshkina, E.B.; Shishov, A.K.; Krivtsova, M.A.; Zhadin, N.N.; Frisman, E.V. The effect of acridine dyes on the molecular structure of DNA. Mol. Biol. (Mosk)., 1975, 9(6), 836-844.
6. Sharma, V.K.; Sahare, P.D.; Rastogi, R.C.; Ghoshal, S.K.; Mohan, D. Excited state characteristics of acridine dyes: acriflavine and acridine orange. Spectrochim. Acta. A Mol. Biomol. Spectrosc., 2003, 59(8), 1799-1804.
7. Mahmood, T.; Paul, A.; Ladame, S. Synthesis and Spectroscopic and DNA-Binding Properties of Fluorogenic Acridine-Containing Cyanine Dyes. J. Org. Chem., 2010, 75(1), 204-207.
8. Browning, C.H. 1967. Proflavine and acriflavine. Br. Med. J., 1967,2(5544), 111.
9. Eiter, L.C.; Hall, N.W.; Day, C.S.; Saluta, G.; Kucera, G.L.; Bierbach U. Gold(I) analogues of a platinum-acridine antitumour agent are only moderately cytotoxic but show potent activity against Mycobacterium tuberculosis. J. Med. Chem., 2009, 52(21), 6519-6522.
10. Wainwright, M. Acridine-a neglected antibacterial chromophore. J. Antimicrob. Chemother., 2001, 47(1),1-13.
11. Novosad, N.V. The antimicrobial activity of thio-, thioxo- and oxoderivatives of acridine. Mikrobiol. Z, 1996, 58(4), 55-58.
12. Gaidukevich, A. N.; Bashura, G.S.; Pertsev, I.M.; Piminov, A.F.; Piatikop, A.I. Determination of the antimicrobial activity of some acridine derivatives. Farm. Zh., 1974, 28(6), 50-54.
13. Loiseau, P.M.; Nguyen, D.X. Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives. Trop. Med. Int. Health. 1996, 1(3), 379-384.
14. Jones, M.; Mercer, A.E.; Stocks, P.A.; La Pensée, L.J.; Cosstick, R.; Park, B.K.; Kennedy, M.E.; Piantanida, I.; Ward, S.A.; Davies, J.; Bray, P.G.; Rawe, S.L.; Baird, J.; Charidza, T.; Janneh, O.; O'Neill, P.M. Antitumour and antimalarial activity of artemisininacridine hybrids. Bioorg. Med. Chem. Lett., 2009, 19(7), 2033-2037.
15. Shibnev, V.A.; Finogenova, M.P.; Grinberg, L.N.; Allakhverdiev, A.M. Synthesis of acridine derivatives of amino acid hydrazines and their antimalarial activity. Bioorg. Khim., 1988, 14(11), 1565-1569.
16. Muth, C.W.; Minigh, H.L.; Chookruvong, S.; Hall, L.A.; Chao, H.T. Syntheses of 9-acridine- and 2-phenanthridinemethanols as potential antimalarials. J. Med. Chem., 1981, 24(8), 1016-1018.
17. Girault, S.; Grellier, P.; Berecibar, A.; Maes, L.; Mouray, E.; Lemière, P.; Debreu, M.A.; Davioud-Charvet, E.; Sergheraert, C. Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker. J. Med. Chem., 2000, 43(14), 2646-2654.
18. Figgitt, D.; Denny, W.; Chavalitshewinkoon, P.; Wilairat, P.; Ralph, R. In vitro study of anticancer acridines as potential antitrypanosomal and antimalarial agents. Antimicrob. Agents. Chemother., 1992, 36(8), 1644-1647.
19. Morales, N.M.; Schaefer, F.W. 3rd; Keller, S.J.; Meyer, R.R. Effects of ethidium bromide and several acridine dyes on the kinetoplast DNA of Leishmania tropica. J. Protozool., 1972, 19(4), 667-672.
20. Mauël, J.; Denny, W.; Gamage, S.; Ransijn, A.; Wojcik, S.; Figgitt, D.; Ralph, R. 9-Anilinoacridines as potential antileishmanial agents. Antimicrob. Agents. Chemother., 1993, 37(5), 991-996.
21. Sasvari, Z.; Bach, S.; Blondel, M.; Nagy, P.D. Inhibition of RNA recruitment and replication of an RNA virus by acridine derivatives with known anti-prion activities. PLoS. One., 2009, 4(10), e7376.
22. Mucsi, I.; Molnár, J.; Tanaka, M.; Santelli-Rouvier, C.; Patelis, A.M.; Galy, J.P.; Barbe, J. Effect of acridine derivatives on the multiplication of herpes simplex virus. Anticancer Res., 1998, 18(4C), 3011-3015.
23. Zeitlenok, N.A.; Pille, E.R.; Konosh O.V. Effect of acridine compounds on multiplication of vaccinia virus. Vopr. Virusol., 1956, 1(2), 16-20.
24. Csuk, R.; Barthel, A.; Brezesinski, T.; Raschke C. Synthesis of dimeric acridine derived antivirals. Bioorg. Med. Chem. Lett., 2004, 14(19), 4983-4985.
25. Lyakhov, S.A.; Suveyzdis, Y.I.; Litvinova, L.A.; Andronati, S.A.; Rybalko, S.L.; Dyadyun, S.T. Biological active acridine derivatives. Part 4: Synthesis and antiviral activity of some bisacridinylated diamides. Pharmazie, 2000, 55(10), 733-736.
26. Gamage, S.A.; Figgitt, D.P.; Wojcik, S.J.; Ralph, R.K.; Ransijn, A.; Mauel, J.; Yardley, V.; Snowdon, D.; Croft, S.L.; Denny, W.A. Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines. J. Med. Chem., 1997, 40(16), 2634-2642.
27. Bonse, S.; Santelli-Rouvier, C.; Barbe, J.; Krauth-Siegel, R.L. Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: kinetic studies and structure-activity relationships. J. Med. Chem., 1999, 42(26), 5448-5454.
28. McSwain, M.L.; Forman, L.M. Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol. J. Clin. Psychopharmacol., 1995, 15(4), 284.
29. Cabeza-Alvarez, C.I.; González-Rubio, M.; García-Montero, R.; Alvarez-Tejerina, A. Parkinsonian syndrome related to tacrine. Neurologia, 1999, 14(2), 96.
30. Csuk, R.; Barthel, A.; Raschke, C.; Kluge, R.; Ströhl, D.; Trieschmann, L.; Böhm, G. Synthesis of monomeric and dimeric acridine compounds as potential therapeutics in Alzheimer and prion diseases. Arch. Pharm.(Weinheim), 2009, 342(12), 699-709.
31. Shutske, G.M.; Pierrat, F.A.; Cornfeldt, M.L.; Szewczak, M.R.; Huger, F.P.; Bores, G.M.; Haroutunian, V.; Davis, K.L. (+/-)-9- Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity. J. Med. Chem., 1988, 31(7), 1278-1279.
32. Ottolenghi-Lodigiani, F. Treatment of chronic lupus erythematosus, local intradermal infiltration with an acridine preparation. Hautarzt., 1955, 6(1), 24-27.
33. Oppegard, L.M.; Ougolkov, A.V.; Luchini, D.N.; Schoon, R.A.; Goodell, J.R.; Kaur, H.; Billadeau, D.D.; Ferguson, D.M.; Hiasa, H. Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II. Eur. J. Pharmacol., 2009, 602(2-3), 223-229.
34. Atwell, G.J.; Cain, B.F.; Seelye, R.N. Potential antitumour agents. 12. 9-Anilinoacridines. J. Med. Chem., 1972, 15(6), 611-615.
35. Cain, B.F.; Seelye, R.N.; Atwell, G.J. Potential antitumour agents. 14. Acridylmethanesulfonanilides. J. Med. Chem., 1974, 17(9), 922-930.
36. Pitta, I.R.; Lima, M.C.A.; Galdino, S.L.; Barbe, J. Molecules with Antitumour Activity and Chemical Synthesis.WO/2004/024058, March 25, 2004.
37. Clinical Trials.gov, Clofarabine or High-Dose Cytarabine, Pegaspargase, and Combination Chemotherapy Followed by Daunorubicin Hydrochloride or Doxorubicin Hydrochloride in Treating Young Patients With Acute Lymphoblastic Leukemia. 2010.
38. Clinical Trials.gov.Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics. 2012.
39. Laufe, L.E.; Sokal, D.C.; Cole, L.P.; Shoupe, D.; Schenken, R.S. Phase I prehysterectomy studies of the transcervical administration of quinacrine pellets. Contraception, 1996, 54(3), 181-186.
40. Gurova, K.V.; Hill, J.E.; Guo, C.; Prokvolit, A.; Burdelya, L.G.; Samoylova, E.; Khodyakova, A.V.; Ganapathi, R.; Ganapathi, M.; Tararova, N.D.; Bosykh, D.; Lvovskiy, D.; Webb, T.R.; Stark, G.R.; Gudkov, A.V. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumours. Proc. Natl. Acad. Sci. U.S.A., 2005, 102(48), 17448-17453.
41. Sklarin, N.T.; Wiernik, P. H.; Grove, W.R.; Benson, L.; Mittelman, A.; Maroun, J.A.; Stewart, J.A.; Robert, F.; Doroshow, J.H.; Rosen, P.J. A phase II trial of CI-921 in advanced malignancies. Invest. New Drugs, 1992, 10(4), 309-312.
42. Dittrich, C.; Coudert, B.; Paz-Ares, L.; Caponigro, F.; Salzberg, M.; Gamucci, T.; Paoletti, X.; Hermans, C.; Lacombe, D.; Fumoleau, P. Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. Eur. j. Cancer, 2003, 39(3), 330-334.
43. Galanis, E.; Buckner, J.C.; Maurer, M.J.; Reid, J.M.; Kuffel, M.J.; Ames, M.M.; Scheithauer, B.W.; Hammack, J.E.; Pipoly, G.; Kuross, S.A. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Invest. New Drugs, 2005, 23(5), 495-503.
44. Su, T.L.; Chou, T.C. Experimental antitumour activity of acridone alkaloids, acronycine and glyfoline. Chin. Pharm. J., 1994, 46(5), 371-391.
45. Koba, M.; Konopa, J. Interactions of antitumour triazoloacridinones with DNA. Acta. Biochim. Pol., 2007, 54(2), 297-306.
46. Burger, A. M.; Dai, F.; Schultes, C.M.; Reszka, A.P.; Moore, M.J.; Double, J.A.; Neidle, S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumour growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005, 65(4), 1489-1496.
47. Chabner, B.A.; Longo, D.L. In: Cancer Chemotherapy and Biotherapy: Principles and Practice, Lippincott William and Wilkins, Ed; Philadelphia, 2010, pp. 451-475.
48. Walker, J.V.; Nitiss, J.L. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest., 2002, 20(4), 570-589.
49. Korth, C.; May, B. C. H.; Cohen, F. E.; Prusiner, S. B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA, 2001, 98(17), 9836-9841.
50. Zawada, Z.; Sebestík, J.; Safarík, P.B. Dependence of the Reactivity of Acridine on Its Substituents: A Computational and Kinetic Study. Eur. J. Org. Chem., 2011, 2011(34), 6989-6997.
51. Upshall, A.; Twardzik, D.R.; Sledziewski, A. Method or treatment of tumours using transforming growth factor-alpha. WO 02/24148 A2, March 28, 2002.
52. Department of Health. Annual Report of the chief medical officer: on the state of public health. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/AnnualReports/DH_076817 (Accessed May 23, 2012).
53. World Health Organization. Radiotherapy risk profile: technical manual. Switzerland, 2008.
54. Symonds, R.P.; Foweraker, K. Principles of chemotherapy and radiotherapy. Curr. Obstet. Gynaecol., 2006, 16, 100-106.
55. Pronzato, P.; Rondini, M. Hormonotherapy of advanced prostate cancer. Ann. Oncol., 2005, 16(Suppl. 4), iv80-iv84.
56. Baxevanis, C.N.; Perez, S.A.; Papamichail, M. Cancer immunotherapy. Crit. Rev. Clin. Lab. Sci., 2009, 4(4), 167-189.
57. Sheng, W.Y.; Huang L. Cancer immunotherapy and nanomedicine. Pharm. Res., 2011, 28(2), 200-214.
58. Lyse, A.N.; Britnie, R.J.; Thomas, S.G. Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.Cancers, 2011, 3(1), 603-620.
59. Chilin, A.; Marzaro, G.; Marzano, C.; Dalla, Via, L.; Ferlin, M.G.; Pastorini, G.; Guiotto, A. Synthesis and antitumour activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity. Bioorg. Med. Chem., 2009, 17(2), 523-529.
60. Lerman, L.S. Structural considerations in the interaction of DNA and acridines. J. Mol. Biol., 1961, 3, 18-30.
61. Lerman, L.S. The structure of the DNA-acridine complex. Proc. Natl. Acad. Sci. U. S. A., 1963, 49,94-102.
62. Strekowski, L.; Wilson, B. Noncovalent interactions with DNA: an overview. Mutat. Res., 2007, 623(1-2), 3-13.
63. Sebestik, J.; Hlavacek, J.; Stibor, I. A role of the 9-aminoacridines and their conjugates in a life science. Curr. Protein. Pept. Sci., 2007, 8(5), 471-483.
64. Wang, W.; Ho, W.C.; Dicker, D.T.; MacKinnon, C.; Winkler, J.D.; Marmorstein, R.; El-Deiry, W.S. Acridine derivatives activate p53 and induce tumour cell death through Bax. Cancer Biol. Ther., 2005, 4(8), 893-898.
65. Malina, A.; Khan, S.; Carlson, C.B.; Svitkin, Y.; Harvey, I.; Sonenberg, N.; Beal, P.A.; Pelletier, J. Inhibitory properties of nucleic acid-binding ligands on protein synthesis. FEBS Lett., 2005, 579(1), 79-89.
66. Alarcon, K.; Demeunynck, M.; Lhomme, J.; Carrez, D.; Croisy, A. Potentiation of BCNU cytotoxicity by molecules targeting abasic lesions in DNA. Bioorg Med Chem., 2001, 9(7), 1901-1910.
67. Turnbull, R.M.; Meczes, E.L.; Perenna Rogers, M.; Lock, R.B.; Sullivan, D.M.; Finlay, G.J.; Baguley, B.C.; Austin, C.A. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta. Cancer Chemother. Pharmacol., 1999, 44(4), 275-282.
68. Denny, W.A. Chemotherapeutic effects of acridine derivatives. Med. Chem. Rev., 2004, 1(3), 257-266.
69. Finlay, G.J.; Atwell, G.J.; Baguley, B.C. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions. Oncol. Res., 1999, 11(6), 249-254.
70. Graziano, M.J.; Courtney, C.L.; Meierhenry, E.F.; Kheoh, T.; Pegg, D.G.; Gough, A.W. Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats. Fundam. Appl. Toxicol., 1996, 32(1), 53-65.
71. Baguley, B.C.; Denny, W.A.; Atwell, G.J.; Finlay, G.J.; Rewcastle, G.W.; Twigden, S.J.; Wilson, W.R. Synthesis, antitumour activity, and DNA binding properties of a new derivative of amsacrine, N-5- dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4- acridinecarboxamide. Cancer. Res., 1984, 44(8), 3245-3251.
72. Bailly, C.; Pommery, N.; Henichart, J.P. DNA-synthesis and tumour growth inhibitions by AGGA, a bleomycin-amsacrine hybrid derivative. Cancer Lett., 1988, 38(3), 321-328.
73. Llama, E.; Del Campo, C.; Capo, M.; Anadon, M. Synthesis and antitumour activity of pyrido-amsacrine analogues and related compounds. J. Pharm. Sci., 1993, 82(3), 262-265.
74. Figgitt, D.P.; Denny, W.A.; Gamage, S.A.; Ralph, R.K. Structureactivity relationships of 9-anilinoacridines as inhibitors of human DNA topoisomerase II. Anticancer Drug. Des., 1994, 9(3), 199-208.
75. Cain, B.F.; Atwell, G.J.; Denny, W.A. Potential antitumour agents. 16.4'-(Acridin-9-ylamino)methanesulfonanilides. J. Med. Chem., 1975, 18(11), 1110-1117.
76. Chang, J.Y.; Lin, C.F.; Pan, W.Y.; Bacherikov, V.; Chou, T.C.; Chen, C.H.; Dong, H.; Cheng, S.Y.; Tasi, T.J.; Lin, Y.W.; Chen, K.T.; Chen, L.T. Su, T.L. New analogues of AHMA as potential antitumour agents: synthesis and biological activity. Bioorg. Med. Chem., 2003, 11(23), 4959-4969.
77. Su, T.L.; Chen, C.H.; Huang, L.F.; Chen, C.H.; Basu, M.K.; Zhang, X.G.; Chou, T.C. Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9- acridinylamino)-5-hydroxymethylaniline. J. Med. Chemi., 1999, 42(23), 4741-4748.
78. Ferlin, M.G.; Marzano, C.; Chiarelotto, G.; Baccichetti, F.; Bordin, F. Synthesis and antiproliferative activity of some variously substituted acridine and azacridine derivatives. Eur. J. Med. Chem., 2000, 35(9), 827-837.
79. Chen, C.H.; Lin, Y.W.; Zhang, X.; Chou, T.C.; Tsai, T.J.; Kapuriya, N.; Kakadiya, R.; Su, T.L. Synthesis and in vitro cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both anilino and acridine rings. Eur. J. Med. Chem.,2009, 44(7), 3056-3059.
80. Sondhi, S.M.; Singh, J.; Rani, R.; Gupta, P.P.; Agrawal, S.K.; Saxena, A.K. Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives. Eur. J. Med. Chem., 2010, 45(2), 555-563.
81. Chen, Y.L.; Chen, I.L.; Lu, C.M.; Tzeng, C.C.; Tsao, L.T.; Wang, J.P. Synthesis and anti-inflammatory evaluation of 9- phenoxyacridine and 4-phenoxyfuro[2,3-b]quinoline derivatives. Part 2. Bioorg. Med. Chem., 2003, 11(18), 3921-3927.
82. Di Giorgio, C.; Delmas, F.; Filloux, N.; Robin, M.; Seferian, L.; Azas, N.; Gasquet, M; Costa, M.; Timon-David, P.; Galy, J.P. In vitro activities of 7-substituted 9-chloro and 9-amino-2- methoxyacridines and their bis- and tetra-acridine complexes against Leishmania infantum. Antimicrob. Agents Chemother., 2003, 47(1),174-180.
83. Konopa, J.; Pawlak, J.W.; Pawlak, K. The mode of action of cytotoxic and antitumour 1-nitroacridines. III. In vivo interstrand cross-linking of DNA of mammalian or bacterial cells by 1- nitroacridines. Chem. Biol. Interact., 1983, 43(2),175-197.
84. Narayanan, R.; Tiwari, P.; Inoa, D.; Ashok, B.T. Comparative analysis of mutagenic potency of 1-nitro-acridine derivatives. Life Sciences, 2005, 77(18), 2312-2323.
85. Yang, P.; Yang, Q.; Qian, X.; Tong, L.; Li, X. Isoquino[4,5- bc]acridines: design, synthesis and evaluation of DNA binding, anti-tumour and DNA photo-damaging ability. J. Photochem. Photobiol. B, 2006, 84(3), 221-226.
86. Osman, S.; Rowlinson-Busza, G.; Luthra, S.K.; Aboagye, E.O.; Brown, G.D.; Brady, F.; Myers, R.; Gamage, S.A.; Denny, W.A.; Baguley, B.C.; Price, P.M. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino) ethyl]acridine-4-carboxamide and DNA-intercalating analogues. Cancer Res., 2001, 61(7), 2935-2944.
87. Pastwa, E.; Ciesielska, E.; Piestrzeniewicz, M.K.; Denny, W.A.; Gniazdowski, M.; Szmigiero, L. Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and its analogues. Biochem. Pharmacol., 1998, 56(3), 351-359.
88. Bridewell, D.J., Finlay, G.J.; Baguley, B.C. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide (DACA). Anticancer Drug. Des., 2001, 16(6), 317-324.
89. Spicer, J.A.; Gamage, S.A.; Atwell, G.J.; Finlay, G.J.; Baguley, B.C.; Denny, W.A. Structure-activity relationships for acridinesubstituted analogues of the mixed topoisomerase I/II inhibitor N- [2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem., 1997, 40(12), 1919-1929.
90. Parajuli, R.; Sarma, R.L.; Das, M.L.; Medhi, C. Model study on the sequence specific stacking by chromophore of an anticancer drug, acridine carboxamide with base pairs of DNA. I.J. Chem, 2007, 46B(9), 1483-1494.
91. Parajuli, R.; Medhi, C. Monitoring the sequence specific intercalation in nucleic acids by 9-substituted acridine-4-carboxamide I. J. Chem., 2006, 45A(1), 146-158.
92. Sugaya, T.; Mimura, Y.; Shida, Y.; Osawa, Y.; Matsukuma, I.; Ikeda, S.; Akinaga, S. Morimoto M, Ashizawa T, Okabe M. 6Hpyrazolo[ 4,5,1-de]acridin-6-ones as a novel class of antitumour agents. Synthesis and biological activity. J. Med. Chem., 1994, 37(7), 1028-1032.
93. Antonini, I.; Polucci, P.; Magnano, A.; Martelli, S. Synthesis, antitumour cytotoxicity, and DNA-binding of novel N-5,2- di(omega-aminoalkyl)-2,6-dihydropyrazolo[3,4,5-kl]acridine-5- carboxamides. J. Med. Chem., 2001, 44(20), 3329-3333.
94. Bu, X.; Chen, J.; Deady, L.W.; Denny, W.A. Synthesis and cytotoxicity of potential anticancer derivatives of pyrazolo[3,4,5- kl]acridine and indolo[2,3-a]acridine. Tetrahedron, 2002, 58(1), 175-181.
95. Antonini, I.; Polucci, P.; Magnano, A.; Sparapani, S.; Martelli, S. Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5- kl]acridine-5-carboxamides) as new anticancer agents. J. Med. Chem., 2004, 47(21), 5244-5250.
96. Liska, K.J. Preparation and antitumour properties of analogs of acronycine. J. Med. Chem., 1972, 15(11), 1177-1179.
97. Costes, N.; Le Deit, H.; Michel, S.; Tillequin, F.; Koch, M.; Pfeiffer, B.; Renard, P.; Léonce, S.; Guilbaud, N.; Kraus-Berthier, L.; Pierré, A.; Atassi, G. Synthesis and cytotoxic and antitumour activity of benzo[b]pyrano[3, 2-h]acridin-7-one analogues of acronycine. 2000, J. Med. Chem. 43(12), 2395-2402.
98. Guilbaud, N.; Kraus-Berthier, L.; Meyer-Losic, F.; Malivet, V.; Chacun, C.; Jan, M.; Tillequin, F.; Michel, S.; Koch, M.; Pfeiffer, B.; Atassi, G.; Hickman, J.; Pierré, A. Marked antitumour activity of a new potent acronycine derivative in orthotopic models of human solid tumours. Clin. Cancer. Res., 2001 7(8), 2573-2580.
99. Guilbaud, N.; Léonce, S.; Tillequin, F.; Koch, M.; Hickman, J.A.; Pierré, A. Acronycine derivatives as promising antitumour agents. Anticancer Drugs, 2002, 13(5),445-449.
100. David-Cordonnier, M.H.; Laine, W.; Lansiaux, A.; Kouach, M.; Briand, G.; Pierré, A.; Hickman, J.A.; Bailly, C. Alkylation of guanine in DNA by S23906-1, a novel potent antitumour compound derived from the plant alkaloid acronycine. Biochemistry.,2002, 41(31), 9911-9920.
101. Braga, P.A.; Dos Santos, D.A.; Da Silva, M.F.; Vieira, P.C.; Fernandes, J.B.; Houghton, P.J.; Fang, R. In vitro cytotoxicity activity on several cancer cell lines of acridone alkaloids and Nphenylethyl- benzamide derivatives from Swinglea glutinosa (Bl.) Merr. Nat. Prod. Res.,2007, 21(1), 47-55.
102. Weniger, B.; Um, B.H.; Valentin, A.; Estrada, A.; Lobstein, A.; Anton, R.; Maillé, M.; Sauvain, M. Bioactive acridone alkaloids from Swinglea glutinosa. J. Nat. Prod., 2001, 64(9), 1221-1223.
103. Stanslas, J.; Hagan, D.J.; Ellis, M.J.; Turner, C.; Carmichael, J.; Ward, W.; Hammonds, T.R.; Stevens, M.F. Antitumour polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines. J. Med. Chem., 2000, 43(8), 1563-1572.
104. Rinehart, K.L.; Holt, T.G.; Fregeau, N.L.; Keifer, P.A.; Wilson, G.R.; Perun, T.J. Jr.; Sakai, R.; Thompson, A.G.; Stroh, J.G.; Shield, L.S. Bioactive compounds from aquatic and terrestrial sources. J Nat Prod., 1990, 53(4), 771-792.
105. Álvarez, M.; Feliu, L.; Ajana, W.; Joule, J.A.; Fernández-Puentes, J.L. Synthesis of Ascididemine and an Isomer. Eur. J. Org. Chem., 2000, 2000(5), 849-855.
106. Delfourne, E.; Roubin, C.; Bastide, J. The first synthesis of the pentacyclic pyridoacridine marine alkaloids: arnoamines A and B. J. Org. Chem., 2000, 65(18), 5476-5479.
107. Radchenko, O. S.; Balaneva, N.N.; Denisenko, V.A.; Novikov, V.L. A simple and effective approach to the synthesis of pyrido[4,3,2-mn]pyrrolo[3,2,1-de]acridine skeleton of arnoamines A and B, pentacyclic marine alkaloids from the ascidian Cystodytes sp. Tetrahedron Lett., 2006,47(44), 7819-7822.
108. Cech, T.R. Life at the End of the Chromosome: Telomeres and Telomerase. Angew. Chem. Int. Ed. Engl., 2000, 39(1), 34-43.
109. Gellert, G.C.; Jackson, S.R.; Dikmen, Z.G.; Wright, W.E.; Shay, J.W. Telomerase as a therapeutic target in cancer. Drug Discov. Today Dis. Mech., 2005, 2(2), 159-164.
110. Kelland, L.R. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects. Eur. J. Cancer, 2005,41(7), 971-979.
111. Harrison, R.J.; Gowan, S.M.; Kelland, L.R.; Neidle, S. Human telomerase inhibition by substituted acridine derivatives. Bioorg. Med. Chem. Lett.,1999, 9(17), 2463-2468.
112. Neidle, S.; Parkinson, G. Telomere maintenance as a target for anticancer drug discovery. Nat Rev Drug Discov., 2002, 1(5), 383-393.
113. Harrison, R.J.; Cuesta, J.; Chessari, G.; Read, M.A.; Basra, S.K.; Reszka, A.P.; Morrell, J.; Gowan, S.M.; Incles, C.M.; Tanious, F.A.; Wilson, W.D.; Kelland, L.R.; Neidle, S. Trisubstituted acridine derivatives as potent and selective telomerase inhibitors. J. Med. Chem., 2003, 46(21), 4463-4476.
114. Gunaratnam, M.; Greciano, O.; Martins, C.; Reszka, A.P.; Schultes, C.M.; Morjani, H.; Riou, J.F.; Neidle, S. Mechanism of acridinebased telomerase inhibition and telomere shortening. Biochem. Pharmacol., 2007, 74(5), 679-689.
115. Zambre, V.P.; Murumkar, P.R.; Giridhar, R.; Yadav, M.R. Structural investigations of acridine derivatives by CoMFA and CoMSIA reveal novel insight into their structures toward DNA Gquadruplex mediated telomerase inhibition and offer a highly predictive 3D-model for substituted acridines. J. Chem. Inf. Model., 2009, 49(5), 1298-1311.
116. Campbell, N.H.; Parkinson, G.N.; Reszka, A.P.; Neidle, S. Structural Basis of DNA Quadruplex Recognition by an Acridine Drug. J. Am. Chem. Soc., 2008, 130(21), 6722-6724.
117. Di Giorgio, C.; Nikoyan, A.; Decome, L.; Botta, C.; Robin, M.; Reboul, J.P.; Sabatier, A.S.; Matta, A.; De Méo, M. DNAdamaging activity and mutagenicity of 16 newly synthesized thiazolo[5,4-a]acridine derivatives with high photo-inducible cytotoxicity. Mutat. Res., 2008, 650(2), 104-114.
118. Cholody, W.M.; Martelli, S.; Konopa, J. 8-Substituted 5- [(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity. J Med Chem., 1990, 33(10), 2852-2856.
119. Kuśnierczyk H, Chołody WM, Paradziej-Lukowicz J, Radzikowski C, Konopa J. Experimental antitumour activity and toxicity of the selected triazolo- and imidazoacridinones. Arch. Immunol. Ther. Exp. (Warsz.), 1994, 42(5-6), 415-423.
120. Lemke, K.; Poindessous, V.; Skladanowski, A.; Larsen, A.K. The antitumour triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol. Pharmacol., 2004, 66(4), 1035-1042.
121. Wesierska-Gadek, J.; Schloffer, D.; Gueorguieva, M.; Uhl, M.; Skladanowski, A. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumour triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Cancer. Res., 2004, 64(13), 4487-4497.
122. Lemke, K.; Wojciechowski, M.; Laine, W.; Bailly, C.; Colson, P.; Baginski, M.; Larsen, A.K.; Skladanowski, A. Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumour activities. Nucleic Acids Res., 2005, 33(18), 6034-6047.
123. Antonini, I.; Polucci, P.; Magnano, A.; Cacciamani, D.; Konieczny, M.T.; Paradziej-Łukowicz, J.; Martelli, S. Rational design, synthesis and biological evaluation of thiadiazinoacridines: a new class of antitumour agents. Bioorg. Med. Chem., 2003, 11(3), 399-405.
124. Denny, W.A.; Atwell, G.J.; Baguley, B.C.; Wakelin, L.P. Potential antitumour agents. 44. Synthesis and antitumour activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity. J. Med. Chem.,1985, 28(11), 1568-1574.
125. Le Pecq, J.B.; Le Bret, M.; Barbet, J.; Roques, B. 1975. DNA polyintercalating drugs: DNA binding of diacridine derivatives. Proc. Natl. Acad. Sci. U. S. A., 1975,72(8), 2915-2919.
126. Barbet, J.; Roques, B.P.; Le Pecq, J.B. DNA-intercalating compounds. Synthesis of acridine dimers. C. R. Acad. Sci. Hebd. Seances Acad. Sci. D, 1975, 281(12), 851-853.
127. Wakelin, L.P.; Romanos, M.; Chen, T.K.; Glaubiger, D.; Canellakis, E.S.; Waring, M.J. Structural limitations on the bifunctional intercalation of diacridines into DNA. Biochemistry, 1978, 17(23), 5057-5063.
128. Chen, T.K.; Fico, R.; Canellakis, E.S. Diacridines, bifunctional intercalators. Chemistry and antitumour activity. J. Med. Chem., 1978, 21(9), 868-874.
129. Spicer, J.A.; Gamage, S.A.; Finlay, G.J.; Denny, W.A. Synthesis and evaluation of unsymmetrical bis(arylcarboxamides) designed as topoisomerase-targeted anticancer drugs. Bioorg. Med. Chem., 2002, 10(1), 19-29.
130. Gamage, S.A.; Spicer, J.A.; Atwell, G.J.; Finlay, G.J.; Baguley, B.C.; Denny, W.A. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents. J. Med. Chem., 1999, 42(13), 2383-2393.
131. Sourdon, V.; Mazoyer, S.; Pique, V.; Galy, J.P. Synthesis of new bis- and tetra-acridines. Molecules, 2001, 6(8), 673-682.
132. Braña, M.F.; Casarrubios, L.; Domínguez, G.; Fernández, C.; Pérez, J.M.; Quiroga, A.G.; Navarro-Ranninger, C.; de Pascual-Teresa, B. Synthesis, cytotoxic activities and proposed mode of binding of a series of bis([(9-oxo-9,10-dihydroacridine-4- carbonyl)amino]alkyl) alkylamines. Eur. J. Med. Chem., 2002, 37(4), 301-313.
133. Augustus, T. M.; Anderson, J.; Hess, S.M.; Bierbach, U. Bis(acridinylthiourea)platinum(II) complexes: synthesis, DNA affinity, and biological activity in glioblastoma cells. Bioorg. Med. Chem. Lett.,2003, 13(5), 855-858.
134. Triesscheijn, M.; Baas, P.; Schellens, J.H.; Stewart, F.A. Photodynamic therapy in oncology. Oncologist, 2006, 11(9), 1034-1044.
135. Fernandez, M.J.; Wilson, B.; Palacios, M.; Rodrigo, M.M.; Grant, K.B.; Lorente, A. Copper-activated DNA photocleavage by a pyridine-linked bis-acridine intercalator. Bioconjug. Chem., 2007, 18(1), 121-129.
136. Vispé, S.; Vandenberghe, I.; Robin, M.; Annereau, J.P.; Créancier, L.; Pique, V.; Galy, J.P.; Kruczynski, A.; Barret, J.M.; Bailly, C. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Biochem. Pharmacol., 2007, 73(12), 1863-1872.
137. Watson, J.D.; Crick, F.H. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature,1953, 171(4356), 737-738.